Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
ACS Medicinal Chemistry Letters2014Vol. 5(4), pp. 422–427
Citations Over TimeTop 10% of 2014 papers
Lee D. Fader, Éric Malenfant, Mathieu Parisien, Rebekah Carson, François Bilodeau, Serge Landry, Marc Pesant, Christian Brochu, Sébastien Morin, Catherine Chabot, Ted Halmos, Yves Bousquet, Murray D. Bailey, Stephen H. Kawai, René Coulombe, Steven R. LaPlante, Araz Jakalian, Punit Kumar Bhardwaj, Dominik Wernic, Patricia Schroeder, Ma’an Amad, Paul Edwards, Michel Garneau, Jianmin Duan, Michael G. Cordingley, Richard C. Bethell, Stephen W. Mason, Michael Bös, Pierre Bonneau, Marc‐André Poupart, Anne‐Marie Faucher, Bruno Simoneau, Craig Fenwick, Christiane Yoakim, Youla S. Tsantrizos
Abstract
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.
Related Papers
- Characterization and structural analysis of HIV-1 integrase conservation.(2009)
- → Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy(2010)73 cited
- → Structure–Photochemical Function Relationships in Nitrogen-Containing Heterocyclic Aromatic Photobases Derived from Quinoline(2020)15 cited
- → Synthesis and HIV-1 Integrase Inhibition Activity of some N-Arylindoles(2008)46 cited
- → Structure-Photochemical Function Relationships in Nitrogen-Containing Heterocyclic Aromatic Photobases Derived from Quinoline(2020)